Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib plus trametinib in pediatric BRAF V600 mutant progressive glioma
jRCTs071210071Completed
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of dabrafenib + trametinib and trametinib in glioma, low-grade glioma (LGG) and high-grade glioma (HGG). Primary endpoint: Best overall response up to 16 weeks after treatment initiation. Started Dec 2021; status: completed.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
gliomalow-grade glioma (LGG)high-grade glioma (HGG)
Beyond the preview
Go deeper on jRCTs071210071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071210071.